ArticleBiomacromolecules2026
Analysis of PTEN Antagonistic Peptides (PAPs) in Neuronal Growth and Traumatic Brain Injury (TBI).
Article in Biomacromolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
PTEN (phosphatase and tensin homologue) is an established cellular growth brake whose inhibition stimulates regeneration of injured neurons in rodent models. Herein, we employed peptide-based PTEN inhibition targeting PTEN's phosphatase activity. Therefore, a fusion peptide (PAP2-TAT) of PAP2 (PTEN antagonistic peptide 2) with TAT (transactivator of transcription) was used to enable cellular entry. PAP2-TAT was not cytotoxic and entered the cytoplasm of primary mouse neurons, where it enhanced neurite growth, growth cone size, and synaptophysin abundance. PAP2-TAT modestly elevated P-AKT and more strongly elevated P-ERK levels. Furthermore, STATs (signal transducer and activator of transcription) were phosphorylated after PAP2-TAT administration. So far, PAPs have not been employed in traumatic brain injury (TBI). In a mouse TBI model, a single PAP2-TAT injection improved single parameters of gait impairments but had no impact on neuroinflammation and TBI-associated weight loss. In summary, peptide-based PTEN inhibition aids neuronal cell growth and regeneration after brain injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.